Trial Profile
A pilot study of Apatinib Mesylate combined with Gifitinib in First-line treatment of Lung Adenocarcinoma with malignant pleural effusion or pericardial effusion
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Jul 2018
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Biomarker; Pharmacodynamics
- 30 Jul 2018 New trial record